Arena Pharmaceuticals' investigational drug APD418 was granted fast track status by the FDA as a treatment for decompensated heart failure.
FDA grants fast track status to Arena Pharma's heart failure drug
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.